Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status.

Abstract

BACKGROUND:

Aggressive pituitary tumours are associated with substantial morbidity and mortality. Treatment options are often limited, and chemotherapy has been reserved as salvage therapy although historically results have often been disappointing. However, temozolomide, an oral alkylating agent, has recently demonstrated significant activity against these tumours. A DNA repair protein, 06-methylguanine-DNA methyltransferase (MGMT) has been suggested as a biomarker to predict response to temozolomide in pituitary tumours.

MATERIALS AND METHODS:

This paper will review the current literature on temozolomide and pituitary tumours and discuss the recent controversy surrounding the value of determining the MGMT status in this tumour group. A PubMed search was performed to retrieve articles, using the terms 'pituitary tumour' and 'temozolomide'.

RESULTS:

Overall, 24/40 (60%) of the published cases demonstrated a response to temozolomide therapy. The highest response rates were seen amongst prolactinomas (73%) and ACTH-secreting tumours (60%), whilst nonfunctioning pituitary tumours exhibit lower response rates (40%). Responsivity is typically evident in the first 3 months of therapy and may be dramatic and sustained. Low MGMT expression, as determined by immunohistochemistry, is associated with a high response rate (76%), whilst high MGMT expression has not been associated with responses. MGMT promoter methylation does not correlate with temozolomide response.

CONCLUSIONS:

Temozolomide is the first chemotherapeutic agent to show substantial response rates in aggressive pituitary tumours. MGMT immunohistochemistry, but not MGMT methylation analysis, shows promise as a predictive tool. Prospective clinical trials are now necessary to more accurately determine the efficacy of this agent in this patient group.

• Authors: Ann I McCormack, John A H Wass, Ashley B Grossman
• Journal: European journal of clinical investigation (Eur J Clin Invest) Vol. 41 Issue 10 Pg. 1133-48 (Oct 2011) ISSN: 1365-2362 [Electronic] England
• PMID: 21496012 (Publication Type: Journal Article)
• Copyright: © 2011 The Authors. European Journal of Clinical Investigation © 2011 Stichting European Society for Clinical Investigation Journal Foundation.

Chemical References

• Antineoplastic Agents, Alkylating
• Biomarkers, Tumor
• Dacarbazine
• O(6)-Methylguanine-DNA Methyltransferase
• Temozolomide

Topics

• Adenoma (drug therapy, metabolism)
• Antineoplastic Agents, Alkylating (therapeutic use)
• Biomarkers, Tumor (metabolism)
• Carcinosarcoma (drug therapy, metabolism)
• Dacarbazine (analogs & derivatives, therapeutic use)
• Humans
• O(6)-Methylguanine-DNA Methyltransferase (metabolism)
• Pituitary Neoplasms (drug therapy, metabolism)
• Temozolomide